Elke van Gorp
YOU?
Author Swipe
View article: Ambler class C-type β-lactamases in<i>Enterobacter</i>spp. and<i>Klebsiella aerogenes</i>in the Netherlands, 2012-2023
Ambler class C-type β-lactamases in<i>Enterobacter</i>spp. and<i>Klebsiella aerogenes</i>in the Netherlands, 2012-2023 Open
We investigated the genomic epidemiology of Ambler class C (AmpC-type) β-lactamases in Enterobacter spp. and Klebsiella aerogenes in the national carbapenemase-producing Enterobacterales (CPE) surveillance of the Netherlands between 2012 a…
View article: Oral ciprofloxacin biofilm activity in a catheter-associated urinary tract infection model
Oral ciprofloxacin biofilm activity in a catheter-associated urinary tract infection model Open
Background Catheter-associated urinary tract infections (CA-UTIs) are a common hospital-acquired infection. We examined ciprofloxacin activity in a novel CA-UTI in vitro model. Methods Three ATCC strains [Escherichia coli (ECO)-25922, Kleb…
View article: Oral ciprofloxacin activity against ceftriaxone-resistant<i>Escherichia coli</i>in an<i>in vitro</i>bladder infection model
Oral ciprofloxacin activity against ceftriaxone-resistant<i>Escherichia coli</i>in an<i>in vitro</i>bladder infection model Open
Objectives Pharmacodynamic profiling of oral ciprofloxacin dosing for urinary tract infections caused by ceftriaxone-resistant Escherichia coli isolates with ciprofloxacin MIC ≥ 0.25 mg/L. Background Urine-specific breakpoints for ciproflo…
View article: Oral fosfomycin activity against <i>Klebsiella pneumoniae</i> in a dynamic bladder infection <i>in vitro</i> model
Oral fosfomycin activity against <i>Klebsiella pneumoniae</i> in a dynamic bladder infection <i>in vitro</i> model Open
Introduction The use of oral fosfomycin for urinary tract infections (UTIs) caused by non-Escherichia coli uropathogens is uncertain, including Klebsiella pneumoniae, the second most common uropathogen. Methods A multicompartment bladder i…
View article: Oral Fosfomycin Treatment for Enterococcal Urinary Tract Infections in a Dynamic <i>In Vitro</i> Model
Oral Fosfomycin Treatment for Enterococcal Urinary Tract Infections in a Dynamic <i>In Vitro</i> Model Open
There are limited treatment options for enterococcal urinary tract infections, especially vancomycin-resistant Enterococcus (VRE). Oral fosfomycin is a potential option, although limited data are available guiding dosing and susceptibility…
View article: Oral Fosfomycin Efficacy with Variable Urinary Exposures following Single and Multiple Doses against <i>Enterobacterales</i> : the Importance of Heteroresistance for Growth Outcome
Oral Fosfomycin Efficacy with Variable Urinary Exposures following Single and Multiple Doses against <i>Enterobacterales</i> : the Importance of Heteroresistance for Growth Outcome Open
Oral fosfomycin trometamol is licensed as a single oral dose for the treatment of uncomplicated urinary tract infections, with activity against multidrug-resistant uropathogens. The impact of interindividual variability in urinary concentr…